Phase I Study of the Combination of MLN9708 and Fulvestrant
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: MLN9708
Sponsor: Dartmouth-Hitchcock Medical Center